AAM
RPRX icon

Advisors Asset Management’s Royalty Pharma RPRX Stock Holding History

Advisors Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,867
Closed -$701K – 1497
2025
Q3 		$701K Sell
19,867
-91
-0.5% -$3.29K 0.01% 894
2025
Q2 		$719K Sell
19,958
-88
-0.4% -$2.92K 0.01% 869
2025
Q1 		$624K Sell
20,046
-178
-0.9% -$5.64K 0.01% 887
2024
Q4 		$516K Buy
20,224
+7,526
+59% +$200K 0.01% 920
2024
Q3 		$359K Buy
+12,698
New +$352K 0.01% 1003
2021
Q2 		– Sell
-1,904
Closed -$83.1K – 1479
2021
Q1 		$83.1K Sell
1,904
-944
-33% -$44.8K ﹤0.01% 1360
2020
Q4 		$143K Buy
+2,848
New +$121K ﹤0.01% 1304

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisors Asset Management's RPRX Position: Q4 2025 in Review

Advisors Asset Management sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 19,867 shares — an estimated $701K sold.

Advisors Asset Management first reported a position in RPRX in Q4 2020 and held it in 7 quarters. The position peaked at $719K in Q2 2025. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Advisors Asset Management reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • Advisors Asset Management sold 19,867 Royalty Pharma shares in Q4 2025, an estimated $701K.
  • Advisors Asset Management first reported a position in Royalty Pharma in Q4 2020 and held it in 7 quarters.
  • Advisors Asset Management's Royalty Pharma position peaked at $719K in Q2 2025.
  • 539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Advisors Asset Management's 13F filing for Q4 2025, filed 12 Feb 2026.